Rainbow Biosciences, LLC (RBCC) + Nano3D Biosciences (n3D) = 3D-Print rival? - 500 Beiträge pro Seite

[rechnerhand]

RBCC Prepares Big Push Into Booming 3D Bioprinting Market
January 16, 2014 05:00 AM Eastern Standard Time

MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--Thanks to new technology innovations pioneered by its partners at Nano3D Biosciences (n3D), Rainbow Coral Corp. (OTCBB: RBCC) is planning a major push into the skyrocketing 3D bioprinting market in 2014.

Rising global demand in the medical industry for new and effective technologies has spurred tremendous interest in applying 3D printing methods to healthcare applications. The next wave of breakthroughs is now occurring in the field of bioprinting, which involves the printing of cell-loaded replicas of human tissues for the purposes of drug testing and regenerative medicine.

With the applications of such cutting-edge technology limited only by the imagination, industry analysts Transparency Market Research predicted last year that the medical 3D printing market will enjoy a compound annual growth rate of 15.4 percent over the next six years, expanding from a value of $345 million in 2012 to nearly a billion dollars in 2019.

RBCC is working closely with n3D to capitalize on this extraordinary growth. The companies are currently engaged in developing and marketing the BiO Assay: the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech made by competitors in the marketplace.

The BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible.

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

http://www.businesswire.com/news/home/20140116005418/en/RBCC…

[rechnerhand]

RBCC Moves to the Front Lines of the 3D Bioprinting Revolution

http://www.marketwatch.com/story/rbcc-moves-to-the-front-lin…

[Betterway]

Antwort auf Beitrag Nr.: 46.259.723 von rechnerhand am 20.01.14 12:44:34

Hey "Rechner...". Spannend, schick mir mal unsere WKN dafür. Hab auch ne Minengesellschaft darunter gefunden ??? will ja nicht die falsche kaufen. Nen Zock ist es Wert. Gruß B. Danke !!

[Betterway]

... was weißt du noch über das Unternehmen ?? Stand ja mal bei 2,50 ?? Wie sollte die - sind ja als Landwirtschaftsunternehmen aufgeführt, in Biotech so top sein ?? Bin skeptisch ?? Gru? B.

[rechnerhand]

Antwort auf Beitrag Nr.: 46.266.075 von Betterway am 21.01.14 10:14:26

Rainbow Coral Aktie ISIN: US75081A2006 | Symbol: RBCC

Rainbow Biosciences ist eine Tochtergesellschaft der Rainbow Coral Corp. (http://rainbowbiosciences.com/company.html)

[Betterway]

... wie sollten die in Biotech so stark, innovativ sein ?? Sind ja als Landwirtschaftsunternehmen gelistet, bzw. aufgeführt ?? Bin skeptisch !! Was weisst du noch darüber ?? Gruß B.

[Betterway]

Antwort auf Beitrag Nr.: 46.266.075 von Betterway am 21.01.14 10:14:26

.. wie sollten die als Biotech - Unternehmen so stark sein ??? Woher das Know - How ?? Sind ja als Landwirtschaftsunternehmen gelistet bzw. aufgeführt. Will man da nur auf nen Zug aufsprigen ?? Bin skeptisch !! Gruß B.

[rechnerhand]

Antwort auf Beitrag Nr.: 46.266.221 von Betterway am 21.01.14 10:30:50

Das Know-How, Großer, kommt aus der Überschrift von der Fa. Nano3D Biosciences (n3D) im Rahmen einer Kooperation ...
Ja, ich denke, die wollen den Zug nicht verpassen, der da ins Rollen kommt.

[Montekaolino]

Antwort auf Beitrag Nr.: 46.266.197 von rechnerhand am 21.01.14 10:27:51

WKN. : A1J0N9.


Bei der DB noch als Gattung gesperrt müßte erst freigeschalter werden.


http://investorshub.advfn.com/Rainbow-Coral-Corp-RBCC-22594/

[Betterway]

Antwort auf Beitrag Nr.: 46.266.243 von rechnerhand am 21.01.14 10:33:27

Hmmmh, die wird in Deutschland gar nicht gehandelt ?? Ist nur direkt bei US Börse zu kaufen ?? Gruß B. Ach ja, woher weisst du, dass ich schon ein "Großer" bin ?? :-) Gruß B.

[rechnerhand]

... hier nochmal etwas in Landessprache dazu.

http://3druck.com/medizin/rbcc-entwickelt-mit-n3d-magnetisch…

[Montekaolino]

Schau mal auf SVFC in USA.

[Montekaolino]

Zitat von Montekaolino: Schau mal auf SVFC in USA.

Ist einer dabei dabei ?

[rechnerhand]

RBCC Explores New Contacts in Personalized Medicine and Drug Delivery

http://www.businesswire.com/news/home/20140122005760/en/RBCC…

[rechnerhand]

RBCC Develops Innovations in White-Hot 3D Bioprinting Sector

http://www.marketwatch.com/story/rbcc-develops-innovations-i…

[rechnerhand]

3D Bioprinting with Rainbow Coral Corp

http://www.nanalyze.com/2014/01/3d-bioprinting-with-rainbow-…

[rechnerhand]

Bioprinting Is Booming and Rainbow Biosciences Wants a Piece

[rechnerhand]

http://www.youtube.com/watch?v=fHWSTx8LLd0

[rechnerhand]

New Product Puts RBCC on Leading Edge of Organ Regeneration Research

http://www.sys-con.com/node/2972753

[rechnerhand]

RBCC: New Innovations Spur Demand for 3D Printing in Medicine

http://www.businesswire.com/news/home/20140220005504/en/RBCC…

[rechnerhand]

RBCC Increases Foothold in 3D Bioprinting Market

http://www.heraldonline.com/2014/02/26/5716146/rbcc-increase…

[Mika_1]

Hi rechnerhand!

Zur Zeit bin ich auf der Suche nach Organovo-Alternativen. Hab mich gerade in Rainbow Biosciences bzw. Rainbow Coral eingelesen.
Sieht sehr interessant aus. Die Aktie ist leider in Deutschland nicht handelbar. Bist Du schon eingestiegen? Kennst Du vielleicht weitere BioPrint-Aktien? Hab diese hier noch bei Twitter entdeckt: Harvard App.Regenerative Tech (WKN:A1T98U).

Viele Grüße
Mika

[rechnerhand]

Antwort auf Beitrag Nr.: 46.550.331 von Mika_1 am 02.03.14 16:15:05

Hi Mika,

nein, leider kann ich damit aktuell nicht dienen.
Was ich Dir adhoc anbieten kann ist folgende Seite.
Da einfach mal auf der linken Seite die derzeit wichtigsten börsennotierten Unternehmen des 3D-Druckbereichs "durchstöbern", ob noch etwas nach Deinem Geschmack ist.

https://3dprintingstocks.com/

[rechnerhand]

Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry

http://www.wallstreet-online.de/nachricht/6619521-rbcc-analy…

[rechnerhand]

Bioprinting Investment Puts RBCC at Forefront of 3-D Revolution

http://www.marketwatch.com/story/bioprinting-investment-puts…

[rechnerhand]

RBCC and n3D Seek Out Additional Capital

http://www.businesswire.com/news/home/20140409005490/en/RBCC…

[Popeye82]

RBCC Bioprinting Partner Expands Brand Awareness Campaign - Apr 16, 2014
http://finance.yahoo.com/news/rbcc-bioprinting-partner-expan…

" Rainbow Coral Corp.’s (RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.

At the 53rd Annual Meeting and ToxExpo of the Society of Toxicology in Phoenix, n3D delivered a poster session presentation titled, “A Novel High-Concept Assay for Drug Toxicity Screening.” The largest event of its kind, the Society’s annual meeting brought together more than 6,000 toxicologists from more than 50 countries.

Earlier this month, n3D shared a booth at the 105th Annual Meeting of the American Association for Cancer Research in San Diego. A premiere cancer research event, the meeting was host to about 18,000 researchers, patient advocates and other professionals in the cancer field from around the world.

By presenting and exhibiting at such landmark events, n3D is helping to spread the word amongst international researchers about its incredible breakthrough technology, the BiO Assay. The BiO Assay is the world’s first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech currently on the market.

“These events are how the latest knowledge in the fields of toxicology and cancer research is spread,” said RBCC CEO Kimberly Palmer. “They are important showcases for new technologies such as the BiO Assay, and they’re only the beginning of the international brand awareness campaign that our joint venture has planned for 2014.”

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (BIIB), Abbott Laboratories (ABT) and Amgen Inc. (AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.


About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html. "

[rechnerhand]

RBCC and n3D Take World’s First Commercially Available 3D Bioprinting System Global


http://www.businesswire.com/news/home/20140522005395/en/RBCC…

[f1re]

Hoert sich sehr interessant an.
Habe heute hier auch mal eine kleine Posi aufgebaut.

[rechnerhand]

RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology


http://online.wsj.com/article/PR-CO-20140611-902761.html

[rechnerhand]

RBCC's injectable technology poised to improve use of addiction treatment drug

http://www.news-medical.net/news/20140611/RBCCs-injectable-t…

[rechnerhand]

RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology

http://www.marketwatch.com/story/rbcc-new-research-could-mas…

[rechnerhand]

Wo bleibt hier eigentlich mal der Q1/2014 report?

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10078…

[rechnerhand]

... eigentlich schon am 03.08.2014 gepostet, aber der Serverausfall hat zur Löschung geführt .. deswegen hier nochmal!

FORM 10-K ANNUAL REPORT FOR 03-31-2014
http://www.sec.gov/Archives/edgar/data/1499790/0001161697140…

"... We incurred a net loss of $1,097,141 for the year ended March 31, 2014. Net cash used by operations for the year ended March 31, 2014 was $531,818. As of March 31, 2014, we had cash on hand of $65,373 and a working capital deficit of $404,118. We do not anticipate having positive net income in the immediate future. These conditions create an uncertainty as to our ability to continue as a going concern. .."

RBCC 3D Bioprinting Partner Awarded Prestigious Grant
http://www.marketwatch.com/story/rbcc-3d-bioprinting-partner…